Identifying carriers of type 2N von Willebrand disease: Procedures and significance

Clinical and Applied Thrombosis/Hemostasis

Volumn 13, Issue 2, 2007, Pages 194-200

  Casonato, A ^a,c   Pontara, E ^a   Sartorello, F ^a   Cattini, M G ^a   Perutelli, P ^a,b   Bertomoro, A ^a   Gallinaro, L ^a   Pagnan, A ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^b Gaslini's Children Hospital   (Italy)

^c UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

FVIII; Type 2N VWD; VWF; VWF:FVIIIB; VWF:FVIIIB ratio

Indexed keywords

BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE MUTATION; HETEROZYGOTE; HUMAN; MISSENSE MUTATION; PARAMETER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VON WILLEBRAND DISEASE;

ADULT; CHILD; FEMALE; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; VON WILLEBRAND DISEASE;

EID: 34047271052     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029606299000     Document Type: Article

References (25)

1. Foster PA, Fulcher CA, Marti T., et al. A major factor VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand factor. J Biol Chem 1987 ; 262: 8443.
2. Fay PJ, Coumans JV, Walker FJ Von Willebrand factor mediates protection of FVIII from activated protein C-catalyzed inactivation. J Biol Chem 1991 ; 266: 2172.
3. Ginsburg D., Sadler JE Von Willebrand disease: A database of point mutations, insertions, and deletions. For the Consortium on von Willebrand Factor mutations and Polymorphisms, and the Subcommitee on von Willebrand factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1993 ; 69: 1024.
4. Nishino M., Girma JP, Rotschild C., et al. A new variant of von Willebrand disease with defective binding to FVIII. Blood 1987 ; 74: 1591.
5. Mazurier C., Jorieux S., Dieval J., et al. A new von Willebrand factor (vWF) defect in a patient with factor VIII (FVIII) deficiency but with normal levels and multimeric pattern of both plasma and platelet vWF. Characterization of abnormal vWF/FVIII interaction. Blood 1990 ; 75: 20.
6. Mazurier C. von Willebrand disease masquerading as haemophilia A. Thromb Haemost 1992 ; 67: 391.
7. Schneppenheim R., Budde U., Krey S., et al. Results of a screening for von Willebrand disease type 2N in patients with suspected haemophilia A or von Willebrand disease type 1. Thromb Haemost 1996 ; 76: 598.
8. Casonato A., Pontara E., Sartorello F., et al. Combined hemophilia A and type 2N von Willebrand's disease: Defect of both factor VIII level and factor VIII binding capacity of von Willebrand factor. Haematol 2001 ; 86: 1110
9. Gaucher C., Jorieux C., Mercier B., et al. The Normandy variant of von Willebrand disease: Characterization of point mutation in the von Willebrand factor gene. Blood 1991 ; 77: 1937.
10. Siguret V., Lavergne JM, Cherel G., et al. A novel case of compound heterozygosity with Normandy/type 1 von Willebrand disease (vWD). Direct demonstration of the segregation of one allele with a defective expression at the mRNA level causing type 1 vWD. Hum Genet 1994 ; 94: 640.
11. Allen S., Abuzenadah AM, Blagg JL, et al. Two novel type 2N von Willebrand disease causing mutations that result in defective factor VIII binding, multimerization and secretion of von Willebrand factor. Blood 2000 ; 95: 2000.
12. Casonato A., Sartorello F., Cattini MG, et al. An Arg760Cys mutation in the consensus sequence of the von Willebrand factor propeptide cleavage site is responsible for a new von Willebrand disease variant. Blood 2003 ; 101: 151.
13. Sadler JE A revised classification of von Willebrand disease. Thromb Haemost 1994 ; 71: 520.
14. Hilbert L., Jorieux S., Proulle V., et al. Two novel mutations, Q1053H and C1060R, located in the D3 domain of von Willebrand factor, are responsible for decreased FVIII-binding capacity. Brit J Haematol 2003 ; 120: 627.
15. Mazurier C., Meyer D. Factor VIII binding assay of von Willebrand factor and the diagnosis of type 2N von Willebrand disease. Results of International Survey. Thromb Haemost 1996 ; 76: 270.
16. Casonato A., Pontara E., Zerbinati P., et al. The evaluation of factor VIII binding activity of von Willebrand factor by means of an ELISA method. Significance and practical implications. Am J Clin Pathol 1998 ; 109: 347.
17. Mancuso DJ, Tuley EA, Westfield LA, et al. Structure of the gene for human von Willebrand factor. J Biol Chem 1989 ; 264: 19514.
18. Eikenboom JC, Reitsma PH, Peerlinck Kmj, Briet E. Recessive inheritance of von Willebrand's disease type I. Lancet 1993 ; 341: 982.
19. Casonato A., Gaucher E., Pontara E., et al. Type 2N von Willebrand disease due to Arg91Gln substitution and a cytosine deletion in exon 18 of the von Willebrand factor gene. Brit J Haematol 1998 ; 103: 39.
20. Leyte A., Voorberg J., Van Schijndel HB, et al. The pro-polypeptide of von Willebrand factor is required for the formation of a functional factor VIII-binding site on mature von Willebrand factor. Biochem J 1991 ; 274: 257.
21. Benedetowicz AV, Robert JA, Wise RJ, et al. Binding of FVIII to von Willebrand factor is enabled by cleavage of the von Willebrand factor propeptide and enhanced by formation of disulfide-linked multimers. Blood 1998 ; 92: 529.
22. Macfarlane DE, Stibbe J., Kirby EP, et al. A method for assaying von Willebrand factor (ristocetin cofactor). Thromb Diath Haemor 1975 ; 34: 306.
23. Weiss HJ Abnormalities of factor VIII and platelet aggregation-use of ristocetin in diagnosing the von Willebrand disease syndrome. Blood 1975 ; 45: 403.
24. Favaloro EJ, Facey D., Graspo L. Laboratory assessment of von Willebrand factor. Use of different assays can influence the diagnosis of von Willebrand's disease, dependent on differing sensitivity to sample preparation and differential recognition of high molecular weight VWF forms. Am J Clin Pathol 1995 ; 104: 264.
25. Casonato A., Pontara E., Bertomoro A., et al. von Willebrand factor collagen binding activity in the diagnosis of von Willebrand disease: An alternative to ristocetin co-factor activity? Brit J Haematol 1999 ; 112: 578.